Belchior Emmanuel, Lévy-Bruhl Daniel, Le Strat Yann, Herida Magid
a Santé Publique France, French National Public Health Agency , Saint-Maurice , France.
Hum Vaccin Immunother. 2016 Sep;12(9):2378-82. doi: 10.1080/21645515.2016.1184801. Epub 2016 Aug 2.
A vaccine against herpes zoster (HZ) and its complications has already proven safe and effective against infection and pain and against the related deterioration of quality of life in the elderly. In order to inform the vaccination decision-making process regarding inclusion of this vaccine in the French immunization schedule, we assessed the cost-effectiveness of several vaccination scenarios, compared to no vaccination. We chose to use a previously published Markov model. Starting vaccination in elderly individuals aged 65, 70 and 75 y old appears more cost-effective than vaccination for those aged 60 y old, with a cost-effectiveness ratio between 30,000 and 35,000 euros per quality-adjusted-life year (QALY) gained for the first 3 age groups versus 54,500 €; for the latter group. These results largely contributed to the recommendation to include the HZ vaccination in the French immunization schedule for people aged between 65 and 74 y old in France.
一种预防带状疱疹（HZ）及其并发症的疫苗已被证明对感染、疼痛以及老年人生活质量的相关恶化具有安全性和有效性。为了为法国免疫规划中纳入该疫苗的疫苗接种决策过程提供信息，我们评估了与不接种疫苗相比的几种疫苗接种方案的成本效益。我们选择使用先前发表的马尔可夫模型。在65岁、70岁和75岁的老年人中开始接种疫苗似乎比在60岁的人群中接种更具成本效益，前三个年龄组每获得一个质量调整生命年（QALY）的成本效益比在30,000至35,000欧元之间，而后者为54,500欧元。这些结果在很大程度上促成了法国将HZ疫苗纳入65至74岁人群的法国免疫规划的建议。
